Virax Biolabs (VRAX) Liabilities and Shareholders Equity (2021 - 2026)

Virax Biolabs' Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $8.3 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 29.53% year-over-year to $8.3 million; the TTM figure through Mar 2026 stood at $29.7 million (down 4.77% YoY), while the FY2026 annual figure was $8.3 million, up 29.53% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $8.3 million, up from $6.4 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $9.8 million in Q1 2023, with the low at $48706.0 in Q1 2022.
• The 5-year median for Liabilities and Shareholders Equity is $7.4 million (2025), against an average of $6.6 million.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity jumped 20046.22% in 2023, then plunged 44.11% in 2024.
• Virax Biolabs' Liabilities and Shareholders Equity stood at $48706.0 in 2022, then surged by 20046.22% to $9.8 million in 2023, then dropped by 3.77% to $9.4 million in 2024, then plunged by 31.94% to $6.4 million in 2025, then gained by 29.53% to $8.3 million in 2026.
• Business Quant data shows VRAX's Liabilities and Shareholders Equity at $8.3 million in Q1 2026, $6.4 million in Q1 2025, and $9.4 million in Q3 2024.